<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.biocentury.com/article/656520/third-death-from-a-sarepta-gene-therapy">Original</a>
    <h1>Third patient dies from acute liver failure caused by a Sarepta gene therapy</h1>
    
    <div id="readability-page-1" class="page"><div><div><div><p>ARTICLE</p><!-- --><p> |</p><!-- --> <!-- --><p>Product Development</p></div>
<div><div><div><h2 doc-editable="title" data-component-id="doc-1fh3men3r0">Patient was in trial of the company’s limb-girdle muscular dystrophy gene therapy</h2><p>July 17, 2025 11:51 PM UTC</p></div></div></div>
<p><span><span></span><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="responsive"/></span></p><p doc-editable="text" data-component-id="doc-1j0dg40u00">A third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy.</p><p doc-editable="text" data-component-id="doc-1j0db69a20">Like <a href="https://www.biocentury.com/article/656215">two deaths</a> associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the most recent death was caused by acute liver toxicity,  <a href="https://profiles.biocentury.com/companies/sarepta_therapeutics_inc">Sarepta Therapeutics Inc.</a> (NASDAQ:SRPT) spokesperson Tracy Sorrentino told BioCentury. ...</p></div></div></div>
  </body>
</html>
